Sunshine Biopharma (SBFM) 0.0095 $SBFM
Sunshine Biopharma Signs Licensing Agreement for Anastrozole, the Company's First Generic Drug for Treatment of Breast Cancer
Marketwire Canada - Wed May 11, 8:15AM CDT
MONTREAL, QC--(Marketwired - May 11, 2016) - Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, is pleased to announce that it has signed a Cross Referencing Agreement with a major pharmaceutical company for Anastrozole, a prescription generic drug for treatment of Breast Cancer. Sunshine will market and sell this new pharmaceutical product under its own label.
Sunshine Biopharma Eliminates the Debt Obligations Associated With the Recently Acquired Patents for Its Adva-27a Anticancer Compound
Marketwired - Tue Mar 15, 8:01AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that it has executed amendments to the patent purchase agreements through which it had acquired all of the worldwide patents and rights to its Adva-27a anticancer compound. The original patent purchase agreements had debt obligations of $17,142,499, including annual and quarterly payments totaling $640,000. The executed amendments reduce the purchase price of the patents, eliminate all cash payments obligations and replace the non-convertible notes totaling $17,142,499 with convertible notes that will automatically convert into an aggregate of 321,305,415 shares of Common Stock upon the Company increasing its authorized capital such that these Common shares can be issued.
What are Investors Looking at - Research on American Green, Sunshine Biopharma, Portlogic Systems and Cellceutix
ACCESSWIRE - Tue Feb 02, 6:40AM CST
NEW YORK, NY / ACCESSWIRE / February 2, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: American Green Inc. (OTC: ERBB), Sunshine Biopharma Inc. (OTC: SBFM), Portlogic Systems Inc. (OTC: PGSY) and Cellceutix Corp. (OTC: CTIX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Sunshine Biopharma Is Moving Forward With Its Development Plans for Adva-27a Anticancer Compound
Marketwire Canada - Wed Jan 20, 8:30AM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that it is moving forward with its plans for the development of Adva-27a and to this end it has recently acquired all of the rights, title and interest in and to all worldwide patents for the Adva-27a anticancer compound. In addition, the Company is currently in discussions with several investment groups for the purposes of securing funding for Adva-27a development through Phase I clinical trials. Adva-27a has proven to be effective at killing Multidrug Resistant Cancer cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells and Uterine Sarcoma cells (Results published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). The Company is planning Phase I clinical trials of Adva-27a on Pancreatic Cancer and, in parallel, Multidrug Resistant Breast Cancer patient volunteers to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).
Sunshine Biopharma Acquires the US Patent for Its Anticancer Compound, Adva-27a
Marketwired - Fri Oct 09, 12:01PM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that it has acquired all of the right, title and interest in and to U.S. Patent Number 8,236,935 for the Company's Adva-27a anticancer compound. The Patent Purchase Agreement executed today provides Sunshine with ownership of the patent, which includes all rights to this intellectual property within the United States. Prior, Sunshine had been licensing the right to use this patent from Advanomics Corporation, a privately held Canadian company that currently owns approximately 23% of Sunshine's issued and outstanding Common Stock. The executed Patent Purchase Agreement also terminates the License Agreement between Sunshine and Advanomics and eliminates all obligations of Sunshine thereunder.
Sunshine Biopharma Announces That the Initial Manufacturing Sample of Its Anticancer Compound Adva-27a Meets Biological Specifications Paving the Way for Clinical Trials
Marketwire Canada - Tue Aug 04, 10:15AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that it has completed analysis of the initial Adva-27a manufacturing sample received in June. The results show that the sample meets all of the biological specifications, clearing the way for the manufacturing of a 2-kilogram quantity for clinical trials.
Sunshine Biopharma to Receive This Week a Sample From the Adva-27a Manufacturing Currently Underway at Lonza in Switzerland
Marketwired - Tue May 26, 8:01AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that Lonza Ltd will ship this week a sample of the Company's Adva-27a anticancer compound for biological testing. Lonza is the Company's cGMP drug manufacturing partner in Switzerland where Adva-27a is currently being manufactured for clinical trials for Pancreatic Cancer and Multidrug Resistant Breast Cancer. Upon receipt of the sample Sunshine will perform a series of standardized cytotoxicity assays and other testing to verify the biological activity of the material and provide feedback to Lonza for the next step in the manufacturing process.
Sunshine Biopharma Announces Issuance of Notice of Allowance for the Patent Application Covering Adva-27a Anticancer Compound in India
GlobeNewswire - Tue Mar 24, 9:00AM CDT
Sunshine Biopharma Inc. (OTCQB:SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer today announced that a "Notice of Allowance" for the patent application covering its lead antitumor compound, Adva-27a, has recently been issued in India. The allowed claims in India are nearly identical to those already issued in the United States (US Patent Number 8,236,935) where Sunshine Biopharma is the exclusive licensee. In addition to the U.S. and India, Adva-27a patents are issued in Europe and Canada. Sunshine Biopharma has previously announced preclinical results showing that Adva-27a has excellent pharmacokinetics profile in rats and remarkable cytotoxic activity against a variety of multidrug resistant cancer cells including breast cancer cells and pancreatic cancer cells. Adva-27a appears to be unique in its ability to destroy multidrug resistant cancer cells. The GMP manufacturing of two kilograms of Adva-27a for clinical trials is currently underway at LONZA LTD in Switzerland. Sunshine Biopharma is planning to conduct the clinical trials of Adva-27a at McGill University's Jewish General Hospital in Montreal, Canada. All aspects of the clinical trials in Canada will be performed in accordance with FDA approved protocols for direct filing of the results in the U.S.
Sunshine Biopharma Signs Agreement With Lonza to Manufacture Its Lead Anti-Cancer Compound, Adva-27a
Marketwire Canada - Wed Nov 19, 10:00PM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today an agreement with Lonza, a leading development and manufacturing company, for the manufacture of its anti-cancer drug, Adva-27a. Lonza's expertise and experience in small molecule development and manufacturing of active pharmaceutical ingredients, was an ideal fit for Sunshine's Adva-27a. Lonza's manufacturing capacity ranges from gram quantities for process validation to kilogram amounts for clinical trials and ton quantities for commercialization. Manufacturing will begin at Lonza's Nansha, China facility with the remaining key steps to be conducted in Lonza's high containment cytotoxic facility in Visp, Switzerland.
Ebola Virus Infections Could Potentially Be Treated With Sunshine Biopharma's Lead Anticancer Compound, Adva-27a
ACCESSWIRE - Mon Nov 03, 4:00AM CST
Montreal, Quebec / ACCESSWIRE / November 3, 2014 / Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has conducted a scientific review of the mechanisms by which Ebola virus penetrates human cells and takes over their machinery to multiply rapidly and go on to infecting other cells leading to massive cell destruction and ultimately death in nearly 80% of the cases. The review found that the progression of Ebola virus infection is very similar to that of Influenza A virus, the causative agent that was responsible for the death of over 90 million people in the 1918 flu pandemic. In severe Influenza A virus infections, a condition associated with high mortality rate called haemophagocytic lymphohistiocytosis (HLH) is developed by the affected patient. HLH has previously been treated successfully with Etoposide which increased survivability from 50% to 90% (LANCET, Volume 367, Pages 870-873, March 2006). Etoposide is an anticancer drug that inhibits the activity Topoisomerase II, an essential enzyme found in hyperactive, rapidly growing cells such as cancer cells and HLH cells. Like Etoposide, Sunshine Biopharma's lead anticancer compound, Adva-27a, is a Topoisomerase II inhibitor however it has been shown to be more effective and less toxic than Etoposide (ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). The latter characteristics make Adva-27a superior to Etoposide for possible treatment of Ebola patients with already weakened state of health.
Sunshine Biopharma Retains Renmark Financial Communications to Provide Investor Relations
Marketwired - Tue Oct 14, 7:06AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, including its proprietary lead anticancer compound Adva-27a, today announced that it has retained the services of Renmark Financial Communications Inc. to handle its investor relations activities.
Sunshine Biopharma's Wholly Owned Canadian Subsidiary Completes the SOP's Required by Health Canada to Secure Drug Establishment License
Marketwire - Wed Oct 01, 7:02AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its wholly owned Canadian subsidiary has completed the drafting of all of the Standard Operating Procedures (SOP's) required by Health Canada for the procurement of a Drug Establishment License (DEL). The completed SOP's comprise 18 binders and over 2,000 pages of documentation. It is necessary for Sunshine to have the DEL in place in order to become a fully integrated pharmaceutical company with proprietary (Adva-27a) and generic pharmaceutical products offering.
Sunshine Biopharma Signs Licensing Agreement for Anastrozole, the Company's First Generic Drug for Treatment of Breast Cancer
Marketwire Canada - Wed May 11, 8:15AM CDT
MONTREAL, QC--(Marketwired - May 11, 2016) - Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, is pleased to announce that it has signed a Cross Referencing Agreement with a major pharmaceutical company for Anastrozole, a prescription generic drug for treatment of Breast Cancer. Sunshine will market and sell this new pharmaceutical product under its own label.
Sunshine Biopharma Eliminates the Debt Obligations Associated With the Recently Acquired Patents for Its Adva-27a Anticancer Compound
Marketwired - Tue Mar 15, 8:01AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that it has executed amendments to the patent purchase agreements through which it had acquired all of the worldwide patents and rights to its Adva-27a anticancer compound. The original patent purchase agreements had debt obligations of $17,142,499, including annual and quarterly payments totaling $640,000. The executed amendments reduce the purchase price of the patents, eliminate all cash payments obligations and replace the non-convertible notes totaling $17,142,499 with convertible notes that will automatically convert into an aggregate of 321,305,415 shares of Common Stock upon the Company increasing its authorized capital such that these Common shares can be issued.
What are Investors Looking at - Research on American Green, Sunshine Biopharma, Portlogic Systems and Cellceutix
ACCESSWIRE - Tue Feb 02, 6:40AM CST
NEW YORK, NY / ACCESSWIRE / February 2, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: American Green Inc. (OTC: ERBB), Sunshine Biopharma Inc. (OTC: SBFM), Portlogic Systems Inc. (OTC: PGSY) and Cellceutix Corp. (OTC: CTIX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Sunshine Biopharma Is Moving Forward With Its Development Plans for Adva-27a Anticancer Compound
Marketwire Canada - Wed Jan 20, 8:30AM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that it is moving forward with its plans for the development of Adva-27a and to this end it has recently acquired all of the rights, title and interest in and to all worldwide patents for the Adva-27a anticancer compound. In addition, the Company is currently in discussions with several investment groups for the purposes of securing funding for Adva-27a development through Phase I clinical trials. Adva-27a has proven to be effective at killing Multidrug Resistant Cancer cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells and Uterine Sarcoma cells (Results published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). The Company is planning Phase I clinical trials of Adva-27a on Pancreatic Cancer and, in parallel, Multidrug Resistant Breast Cancer patient volunteers to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).
Sunshine Biopharma Acquires the US Patent for Its Anticancer Compound, Adva-27a
Marketwired - Fri Oct 09, 12:01PM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that it has acquired all of the right, title and interest in and to U.S. Patent Number 8,236,935 for the Company's Adva-27a anticancer compound. The Patent Purchase Agreement executed today provides Sunshine with ownership of the patent, which includes all rights to this intellectual property within the United States. Prior, Sunshine had been licensing the right to use this patent from Advanomics Corporation, a privately held Canadian company that currently owns approximately 23% of Sunshine's issued and outstanding Common Stock. The executed Patent Purchase Agreement also terminates the License Agreement between Sunshine and Advanomics and eliminates all obligations of Sunshine thereunder.
Sunshine Biopharma Announces That the Initial Manufacturing Sample of Its Anticancer Compound Adva-27a Meets Biological Specifications Paving the Way for Clinical Trials
Marketwire Canada - Tue Aug 04, 10:15AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that it has completed analysis of the initial Adva-27a manufacturing sample received in June. The results show that the sample meets all of the biological specifications, clearing the way for the manufacturing of a 2-kilogram quantity for clinical trials.
Sunshine Biopharma to Receive This Week a Sample From the Adva-27a Manufacturing Currently Underway at Lonza in Switzerland
Marketwired - Tue May 26, 8:01AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that Lonza Ltd will ship this week a sample of the Company's Adva-27a anticancer compound for biological testing. Lonza is the Company's cGMP drug manufacturing partner in Switzerland where Adva-27a is currently being manufactured for clinical trials for Pancreatic Cancer and Multidrug Resistant Breast Cancer. Upon receipt of the sample Sunshine will perform a series of standardized cytotoxicity assays and other testing to verify the biological activity of the material and provide feedback to Lonza for the next step in the manufacturing process.
Sunshine Biopharma Announces Issuance of Notice of Allowance for the Patent Application Covering Adva-27a Anticancer Compound in India
GlobeNewswire - Tue Mar 24, 9:00AM CDT
Sunshine Biopharma Inc. (OTCQB:SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer today announced that a "Notice of Allowance" for the patent application covering its lead antitumor compound, Adva-27a, has recently been issued in India. The allowed claims in India are nearly identical to those already issued in the United States (US Patent Number 8,236,935) where Sunshine Biopharma is the exclusive licensee. In addition to the U.S. and India, Adva-27a patents are issued in Europe and Canada. Sunshine Biopharma has previously announced preclinical results showing that Adva-27a has excellent pharmacokinetics profile in rats and remarkable cytotoxic activity against a variety of multidrug resistant cancer cells including breast cancer cells and pancreatic cancer cells. Adva-27a appears to be unique in its ability to destroy multidrug resistant cancer cells. The GMP manufacturing of two kilograms of Adva-27a for clinical trials is currently underway at LONZA LTD in Switzerland. Sunshine Biopharma is planning to conduct the clinical trials of Adva-27a at McGill University's Jewish General Hospital in Montreal, Canada. All aspects of the clinical trials in Canada will be performed in accordance with FDA approved protocols for direct filing of the results in the U.S.
Sunshine Biopharma Signs Agreement With Lonza to Manufacture Its Lead Anti-Cancer Compound, Adva-27a
Marketwire Canada - Wed Nov 19, 10:00PM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today an agreement with Lonza, a leading development and manufacturing company, for the manufacture of its anti-cancer drug, Adva-27a. Lonza's expertise and experience in small molecule development and manufacturing of active pharmaceutical ingredients, was an ideal fit for Sunshine's Adva-27a. Lonza's manufacturing capacity ranges from gram quantities for process validation to kilogram amounts for clinical trials and ton quantities for commercialization. Manufacturing will begin at Lonza's Nansha, China facility with the remaining key steps to be conducted in Lonza's high containment cytotoxic facility in Visp, Switzerland.
Ebola Virus Infections Could Potentially Be Treated With Sunshine Biopharma's Lead Anticancer Compound, Adva-27a
ACCESSWIRE - Mon Nov 03, 4:00AM CST
Montreal, Quebec / ACCESSWIRE / November 3, 2014 / Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has conducted a scientific review of the mechanisms by which Ebola virus penetrates human cells and takes over their machinery to multiply rapidly and go on to infecting other cells leading to massive cell destruction and ultimately death in nearly 80% of the cases. The review found that the progression of Ebola virus infection is very similar to that of Influenza A virus, the causative agent that was responsible for the death of over 90 million people in the 1918 flu pandemic. In severe Influenza A virus infections, a condition associated with high mortality rate called haemophagocytic lymphohistiocytosis (HLH) is developed by the affected patient. HLH has previously been treated successfully with Etoposide which increased survivability from 50% to 90% (LANCET, Volume 367, Pages 870-873, March 2006). Etoposide is an anticancer drug that inhibits the activity Topoisomerase II, an essential enzyme found in hyperactive, rapidly growing cells such as cancer cells and HLH cells. Like Etoposide, Sunshine Biopharma's lead anticancer compound, Adva-27a, is a Topoisomerase II inhibitor however it has been shown to be more effective and less toxic than Etoposide (ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). The latter characteristics make Adva-27a superior to Etoposide for possible treatment of Ebola patients with already weakened state of health.
Sunshine Biopharma Retains Renmark Financial Communications to Provide Investor Relations
Marketwired - Tue Oct 14, 7:06AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, including its proprietary lead anticancer compound Adva-27a, today announced that it has retained the services of Renmark Financial Communications Inc. to handle its investor relations activities.
Sunshine Biopharma's Wholly Owned Canadian Subsidiary Completes the SOP's Required by Health Canada to Secure Drug Establishment License
Marketwire - Wed Oct 01, 7:02AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its wholly owned Canadian subsidiary has completed the drafting of all of the Standard Operating Procedures (SOP's) required by Health Canada for the procurement of a Drug Establishment License (DEL). The completed SOP's comprise 18 binders and over 2,000 pages of documentation. It is necessary for Sunshine to have the DEL in place in order to become a fully integrated pharmaceutical company with proprietary (Adva-27a) and generic pharmaceutical products offering.
